Matter Bio

Based in Delaware, US, and co-founded by Chris Bradley (CEO) and Sam Sharifi in 2022, Matter Bioworks operates as a biotechnology company offering a platform that focuses on preserving and intervening in information loss for genome integrity.  The biotech company addresses the issue of information loss within our genomes, which is a key driver of aging. As humans age, their genomes are constantly exposed to damage from both external and internal sources, leading to errors such as mutations, structural variations, and epigenetic drift. Matter Bioworks has adopted a hub-and-spoke model, intervening at four crucial stages of information loss, which include recognizing the loss of information, enhancing repair mechanisms to prevent accumulation, repairing integrated mutations, and eliminating cells that have become too mutated to revert, such as cancerous, clonal, and senescent cells. Matter Bio operates through subsidiary companies, each specializing in unique aspects of genome integrity. Spellcheck Bio offers a precise DNA editing method to detect and fix somatic mutations surgically. Loki Therapeutics develops immune therapies that can overcome the challenges presented by mutagenic tumors. MutagenTech provides single-cell sequencing solutions for detecting point mutations, offering efficiency and cost-effectiveness compared to other methods.

1. Seed

   May 29, 2024

   Amount

   $7M

   Investors

   Locked